Inflammation Is Necessary for Long-Term but Not Short-Term High-Fat Diet–Induced Insulin Resistance
- Yun Sok Lee1,2,3,
- Pingping Li3,
- Jin Young Huh1,2,
- In Jae Hwang1,2,
- Min Lu3,
- Jong In Kim1,2,
- Mira Ham1,2,
- Saswata Talukdar3,
- Ai Chen3,
- Wendell J. Lu3,
- Guatam K. Bandyopadhyay3,
- Reto Schwendener4,
- Jerrold Olefsky3 and
- Jae Bum Kim1,2,5⇓
- 1Institute of Molecular Biology and Genetics, Seoul National University, Seoul, Korea
- 2School of Biological Sciences, Seoul National University, Seoul, Korea
- 3Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, La Jolla, California
- 4Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland
- 50Department of Biophysics and Chemical Biology, Seoul National University, Seoul, Korea
- Corresponding author: Jae Bum Kim, .
Y.S.L., P.L., and J.Y.H. contributed equally to this study.
OBJECTIVE Tissue inflammation is a key factor underlying insulin resistance in established obesity. Several models of immuno-compromised mice are protected from obesity-induced insulin resistance. However, it is unanswered whether inflammation triggers systemic insulin resistance or vice versa in obesity. The purpose of this study was to assess these questions.
RESEARCH DESIGN AND METHODS We fed a high-fat diet (HFD) to wild-type mice and three different immuno-compromised mouse models (lymphocyte-deficient Rag1 knockout, macrophage-depleted, and hematopoietic cell-specific Jun NH2-terminal kinase–deficient mice) and measured the time course of changes in macrophage content, inflammatory markers, and lipid accumulation in adipose tissue, liver, and skeletal muscle along with systemic insulin sensitivity.
RESULTS In wild-type mice, body weight and adipose tissue mass, as well as insulin resistance, were clearly increased by 3 days of HFD. Concurrently, in the short-term HFD period inflammation was selectively elevated in adipose tissue. Interestingly, however, all three immuno-compromised mouse models were not protected from insulin resistance induced by the short-term HFD. On the other hand, lipid content was markedly increased in liver and skeletal muscle at day 3 of HFD.
CONCLUSIONS These data suggest that the initial stage of HFD-induced insulin resistance is independent of inflammation, whereas the more chronic state of insulin resistance in established obesity is largely mediated by macrophage-induced proinflammatory actions. The early-onset insulin resistance during HFD feeding is more likely related to acute tissue lipid overload.
Chronic tissue inflammation is an important cause of insulin resistance in obesity. A number of studies have demonstrated increased accumulation of adipose tissue macrophages (ATMs) in obese humans and rodents (1,2), and it is likely that macrophage-induced proinflammatory signaling is a key mediator of obesity-induced tissue inflammation. It has also been shown that a specific subpopulation of CD11c+, M1-like macrophages account for the majority of the increased ATM content, and these macrophages secrete a variety of cytokines that cause decreased insulin sensitivity through both paracrine and endocrine mechanisms (3–5). A number of additional studies have shown that genetic deletion of macrophage inflammatory pathway components has a marked effect to protect against obesity-induced insulin resistance and glucose intolerance (6–8).
In addition to this inflammatory mechanism, it is also known that lipid overload can cause insulin resistance. Thus, acute administration of lipid infusions to humans and rodents rapidly causes decreased insulin sensitivity through mechanisms that still remain to be completely defined (9–11). In addition, insulin-resistant adipose tissue displays enhanced rates of lipolysis and the increased circulating free fatty acid (FFA) levels can cause decreased insulin sensitivity through a process called lipotoxicity (12). However, in obesity, the relative roles of inflammation and lipotoxicity as causes of insulin resistance remain to be fully defined.
Here, we have conducted detailed high-fat diet (HFD) time course studies in wild-type and immuno-compromised mouse models, such as macrophage- or lymphocyte-depleted mice, or hematopoietic cell-specific Jun NH2-terminal kinase (JNK)–deficient mice, to assess whether inflammation triggers systemic insulin resistance or vice versa in obesity.
RESEARCH DESIGN AND METHODS
Animals and treatments.
Seven-week-old male C57BL/6J mice were obtained from Daehan-Biolink (Korea) or The Jackson Laboratory and were housed in colony cages in 12-h light/12-h dark cycles. Rag1 knockout (KO) mice were purchased from The Jackson Laboratory. After a minimum 1-week stabilization period, mice (8 weeks old) were fed normal chow diet (NCD) until they were subjected to 60% HFD for the indicated time periods (Research Diets, Inc.). Thus, on the day of death, all of the HFD mice were compared with age-matched chow-fed mice. The average initial body weights in each group of mice were not different. For oral glucose tolerance test, the mice were fasted for 6 h and basal blood samples were taken, followed by oral glucose injection (1 g/kg). Blood samples were drawn at 10, 30, 60, 90, and 120 min after injection. Mouse clamp experiments were performed as described previously (13). Insulin-stimulated glucose disposal rate (ISGDR) was calculated as: ISGDR = glucose disposal rate (GDR; during the clamp) − basal GDR. Therefore, this value represents a measurement of the increase in GDR from the basal value (basal hepatic glucose production [HGP] = basal GDR = basal Ra) as a result of the insulin infused in the clamp. Because basal GDR is the same as basal HGP, the equation could also be ISGDR = GDR (during the clamp) − basal HGP. We calculated the total GDR during the clamp in the traditional way as glucose infusion rate (GIR) + HGP (during the clamp). During the clamps, insulin was infused at a constant rate of 8.0 mU/kg/min. For the clodronate experiments, liposome-encapsulated clodronate (100 mg/kg) was intraperitoneally injected into the mice 3 days before the onset of HFD (as a single injection), which was followed by the second and third injections every 3 days (14). Homeostasis model assessment of insulin resistance was calculated using the following formula: fasting glucose (mg/dL) × fasting insulin (mU/L)/405. Hematopoietic cell-specific JNK-deficient mice were generated as described previously (6). All animal procedures were in accordance with the research guidelines for the use of laboratory animals of Seoul National University and the University of California San Diego.
Flow cytometry analysis.
Fluorescence-activated cell sorter analysis (FACS) of stromal vascular cells (SVCs) was performed as described previously (15,16). Epididymal adipose tissue were weighed, rinsed three times in PBS, and then minced in FACS buffer (PBS supplemented with 1% low endotoxin BSA). Tissue suspensions were centrifuged at 500g for 5 min and then collagenase-treated (1 mg/mL; Sigma-Aldrich) for 30 min at 37°C with shaking. Cell suspensions were filtered through a 100 μm mesh and centrifuged at 500g for 5 min. SVC pellets were then incubated with erythrocyte lysis buffer (ebioscience) for 5 min before centrifuge (300g; 5 min) and resuspended in FACS buffer. SVCs were incubated with Fc block for 20 min at 4°C before staining with fluorescence labeled primary antibodies or control IgGs for 30 min at 4°C. F4/80-APC FACS antibody was purchased from AbD Serotec (Raleigh, NC); CD11b-fluorescein isothiocyanate and CD11c-PE FACS antibodies were from BD Biosciences. Cells were gently washed twice and resuspended in FACS buffer with propidium iodide (PI) (Sigma-Aldrich). For Foxp3 staining (ebioscience), SVCs were fixed with Foxp3 staining buffer (ebioscience). After incubation for 5 min at 4°C, cells were washed and then incubated with the fluorescein isothiocyanate-Foxp3 antibody for 30 min at 4°C. SVCs were analyzed using a FACS Aria flow cytometer (BD Biosciences). Unstained, single stains and Fluorescence Minus One controls were used for setting compensation and gates. The events are first gated based on forward versus side scatter area, as well as side scatter height versus width for a total of three dual parameter plots to gate out aggregates and debris. We used single color controls to calculate compensation using the FACSDiva software. A plot of forward scatter versus PI fluorescence was used as the fourth gate to identify individual, live cells. To measure markers with the maximum sensitivity, each fluorochrome was plotted versus PI and polygons were drawn, angled with the aid of the Fluorescence Minus One controls. This excluded dead and autofluorescent cells, but included dim positives. By using polygon gates in combination with logical gates, inclusion of false-positive cells in the gates was reduced.
Glucose uptake assay.
Glucose uptake assays were performed as described previously (17).
Macrophage migration assays.
Migration of macrophages was measured using Transwell plates (Corning) with a pore size of 8.0 μm. Raw264.7 macrophages were loaded on a top plate. After 3 h, the cells were washed with Dulbecco’s modified Eagle’s medium supplemented with 0.2% BSA, and the Transwells were transferred to new plates with different adipocyte conditioned media (ACM). Wells were removed, and the cells on the top of the insert or the bottom were scraped and counted by a hematocytometer. The migration rate (%) is the percentage of cells in the bottom versus the total cells in both the bottom and the top. For preparation of ACM, primary adipocytes from lean control or 3-day HFD-treated mice were incubated in Dulbecco’s modified Eagle’s medium supplemented with 0.2% BSA for 12 h.
Whole-mount immunohistochemistry was performed as described previously (18).
Lipid content measurement.
Levels of lipid contents in liver and skeletal muscle of NCD or HFD mice were measured as described previously (19).
The results are shown as means ± SEM. All statistical analysis was performed by Student t test or ANOVA in Excel (Microsoft); P < 0.05 was considered significant.
Effect of short-term HFD on body weight, fat pad mass, and adipocyte size.
To determine the temporal transition point when adipose dysfunction begins, C57BL/6J mice were fed a 60% HFD for 3 days and 1, 2, 5, and 10 weeks, and body weight, epididymal adipose tissue mass, and adipocyte size were measured at each time point. At the day of death, all mice were the same age (18 weeks old) in both NCD and HFD groups. Body weight, epididymal adipose tissue mass, and adipocyte size were significantly increased after only 3 days of HFD, and these changes progressed thereafter (Fig. 1). Interestingly, during the first 3 to 4 days of HFD, mice consumed ∼30% more food (data not shown) than before or 1 week after HFD regimen, leading to an abrupt increase of body weight during this period, which subsides to a lower rate of increase thereafter. In adipose tissue, the expression of genes involved in lipid storage such as SREBP1, FAS, PPAR-γ, LXR-α, and perilipin were greatly promoted at 3 days of HFD (Supplementary Fig. 1).
Time course of glucose intolerance and insulin resistance on HFD.
To examine whether the increased body weight and adipose tissue mass induced by short-term HFD were associated with systemic insulin resistance, we performed glucose tolerance tests. Mice fed an HFD for only 3 days showed significantly impaired glucose tolerance comparable with that after 10 weeks of HFD (Fig. 2A). Plasma insulin levels were also elevated by 3 days of HFD (Fig. 2B), further indicating the onset of systemic insulin resistance.
To gain better insight into the in vivo effects of short-term HFD, we performed hyperinsulinemic-euglycemic clamp studies. Basal glucose levels began to rise as early as 3 days of HFD (Fig. 2C), and this was accompanied by an increase in basal HGP rates (Fig. 2D). These results are consistent with the view that increased basal HGP is the key determinant of basal hyperglycemia. In contrast, the GIR progressively fell, beginning at 3 days with a maximal decrement at 10 weeks of HFD (Fig. 2E), demonstrating the onset and progression of systemic insulin resistance. This was accompanied by a gradual decline in ISGDR (Fig. 2F) and an impaired ability of insulin to suppress HGP (Fig. 2G; Supplementary Fig. 2) and circulating FFA levels (Fig. 2H). These in vivo data strongly demonstrate that 3 days of HFD is sufficient to cause decreased insulin sensitivity in muscle, liver, and fat and that the magnitude of the insulin resistance worsens through 10 weeks. It is also evident that the time of onset of insulin resistance and its incremental progression over 10 weeks is comparable in the three major insulin target tissues, liver, muscle, and fat, as indicated by the similar rate of decline in percent HGP suppression, ISGDR, and percent FFA suppression, respectively.
It is well established that adipose tissue dysfunction can contribute to systemic insulin resistance by modulating insulin action in liver and muscle through secreted adipocytokines. To assess this, we measured circulating levels of adiponectin, interleukin (IL)-6, and tumor necrosis factor (TNF)-α. Plasma levels of adiponectin decreased, whereas plasma IL-6 and TNF-α concentrations were increased at 3 days of HFD (Supplementary Fig. 2), without further changes by 10 weeks. These results suggest that rapid dysregulation of adipocytokine production might contribute to the systemic insulin resistance upon short-term HFD.
Effects on adipose tissue inflammation.
Adipose tissue inflammation involves increased ATM content with polarization of ATMs into a proinflammatory phenotype, often referred to as M1-like polarization in which ATMs express high levels of CD11c as well as F4/80 and CD11b (3). As shown in Fig. 3A, flow cytometry analyses revealed that the total number of F4/80 and CD11b double-positive ATMs were elevated in adipose tissue by 3 days of HFD (panel i), and a large proportion of these macrophages also expressed CD11c (triple positive, F4/80+, CD11b+, and CD11c+ proinflammatory M1 ATMs; panel ii). This increase in CD11c+ ATM content was also present when data were normalized to total epididymal adipose tissue mass, or total SVC number (%SVCs), showing that proinflammatory macrophages accumulate in adipose tissue shortly after HFD (data not shown). Furthermore, the ratio of CD11c+ ATMs to total ATMs was increased at 3 days of HFD (Fig. 3A, panel iii). On the other hand, the ratio of CD11c− ATMs (F4/80+/CD11b+/CD11c−) (%SVCs) was not increased by 3-day HFD (data not shown), although the total number of CD11c− ATMs increased (Fig. 3A, panel iv). Therefore, these results indicate that the proinflammatory M1 polarization of ATMs occurs concomitantly with increased ATM content.
Regulatory T cells (Tregs) are an anti-inflammatory immune cell type and the total number of Tregs was not changed after HFD (Fig. 3A, panel v). However, the ratio of Tregs to the total number of SVCs (data not shown) or to the total number of CD11c+ macrophages (Fig. 3A, panel vi) was decreased at 3 days of HFD, remaining equally reduced through 10 weeks. This was because of the increase in ATMs with no absolute change in Treg numbers. Consistent with these FACS data, two-dimensional (paraffin-section; Fig. 3B) and three-dimensional (whole-mount; Fig. 3C) immunohistochemistry analyses also showed an increase in ATMs by 3 days of HFD.
To determine whether these changes in ATM content during short-term HFD are associated with increased inflammatory gene expression, we assessed mRNA levels of proinflammatory genes by quantitative RT-PCR. As illustrated in Fig. 4 and Supplementary Fig. 3, proinflammatory gene expression was selectively augmented in white adipose tissue after 3 to 7 days of HFD. The increase in proinflammatory gene expression was detected in both the adipocyte and SVC fractions (Supplementary Fig. 3), although the quantitative changes were much greater in the SVCs.
To test whether increased ATM content is associated with increased adipocyte chemoattractant activity, we isolated primary adipocytes from lean control and 3- and 7-day HFD-treated mice and collected ACM from each group. Raw264.7 macrophages were then incubated with ACM in Transwell plates to measure chemotaxis activity. As shown in Fig. 5A, macrophage migration was significantly increased with ACM prepared from HFD-treated mice compared with ACM from control chow-fed mice. Consistent with this, monocyte chemoattractant protein (MCP)-1 expression and secretion from primary adipocytes from HFD mice were significantly increased (Fig. 5B and C). In adipose tissue, interestingly, whereas HFD led to a large increase in MCP-1 expression in adipocytes, the expression of MCP-1 in the SVC fraction was unchanged at the end of the 7-day HFD period (Supplementary Fig. 3). In contrast, TNF-α and IL-6 expression was predominantly from SVCs, not adipocytes (Supplementary Fig. 3). These data indicate that enhanced macrophage infiltration into adipose tissue after short-term HFD is a result of increased adipocyte-derived chemoattractive activity.
Lymphocytes are not necessary for short-term HFD-induced insulin resistance.
To examine the potential role of lymphocytes in the systemic insulin resistance and adipose tissue inflammation induced by short-term HFD, we used lymphocyte-deficient Rag1 KO mice. Consistent with previous reports (20), NCD-fed Rag1 KO mice showed higher levels of basal ATM infiltration and M1 polarization than those of wild-type mice (Fig. 6A). After 1 week of HFD, a significant increase in ATM infiltration and M1 polarization was observed in Rag1 KO mice along with increased fat mass and inflammatory gene expression (Fig. 6A–C). Additionally, Rag1 KO mice developed glucose intolerance as early as 3 days of HFD with increased blood insulin levels (Fig. 6D and E). Moreover, insulin tolerance tests indicated that Rag1 KO mice exhibited a similar level of insulin resistance as wild-type mice by 1-week HFD (Fig. 6F). In vitro glucose uptake assays showed that primary adipocytes from 1-week HFD-fed Rag1 KO mice were insulin resistant (Fig. 6G). Together, these results suggest that lymphocytes are not necessary for short-term HFD-induced adipose dysfunction and insulin resistance.
Macrophages are not critical for short-term HFD-induced insulin resistance.
To determine whether macrophages are essential for the initiation of HFD-induced insulin resistance, we tested the effect of clodronate-mediated depletion of macrophages on insulin sensitivity in 3-day HFD-fed mice. After clodronate injection (48 h), ATMs were depleted by 80%, and this effect was sustained for up to 3 days (Fig. 7A). Under the same conditions, there were no detectable changes in adipocyte size or morphology (Fig. 7B). Despite that, serum levels of proinflammatory cytokines such as IL-6 and TNF-α were significantly decreased by clodronate (Fig. 7C). Interestingly, glucose uptake assays in primary adipocytes revealed that clodronate-mediated depletion of macrophages did not restore the HFD-induced decrease in insulin-stimulated glucose uptake (Fig. 7D). Moreover, clodronate treatment did not improve glucose tolerance or insulin resistance in mice fed an HFD for 3 or 7 days (Fig. 7E–G). Because clodronate targets all phagocytic cell populations, including hepatic Kupffer cells (Supplementary Fig. 4), we also tested the Kupffer cell inhibitor, gadolinium. Similar to clodronate, gadolinium did not affect 1-week HFD-induced glucose intolerance (Supplementary Fig. 5). In marked contrast, both clodronate and gadolinium significantly improved glucose tolerance in long-term (14-week) HFD-treated mice (Supplementary Fig. 6) or obese/diabetic db/db mice (data not shown). These results are consistent with our previous report that depletion of proinflammatory macrophages readily reverses the insulin resistance in well-established obesity (7). Thus, these data suggest that ATMs and Kupffer cells do not play a critical role in the insulin resistance caused by short-term HFD but are essential for the development of insulin resistance after long-term (14-week) HFD.
To assess this concept with an alternative approach, we determined the effect of suppressing proinflammatory activity in immune cells using hematopoietic cell-specific JNK-deficient mice. Previously, we have shown that hematopoietic cell-specific JNK deficiency protects mice from long-term HFD-induced insulin resistance (6). As shown in Fig. 7H–J, hematopoietic cell-specific JNK deficiency did not ameliorate short-term HFD-induced insulin resistance. These results are consistent with the idea that macrophage-mediated inflammation is necessary for the insulin resistance associated with long-term HFD/obesity, but not as a result of short-term HFD.
Ceramide accumulates in liver and muscle acutely after HFD.
A number of studies have shown that insulin resistance in obesity is associated with activation of intracellular diacylglycerol (DAG)/protein kinase C (PKC)θ and ceramide pathways (10,21). To determine whether lipid overload as a result of short-term HFD is associated with systemic insulin resistance, we measured various lipid components in liver and skeletal muscle of NCD mice after 3 days of HFD. As shown in Fig. 8, levels of triacylglycerol, nonesterified fatty acids (NEFA), DAG, and ceramide were all significantly increased in liver and skeletal muscle by 3 days of HFD. Of interest, clodronate treatment did not affect short-term HFD-induced accumulation of DAG, ceramide, and NEFA in liver and skeletal muscle, whereas it blunted triacylglycerol content (Fig. 8).
Here, we have evaluated the in vitro and in vivo initiation and progression of inflammation and insulin resistance during the development of obesity in HFD-fed mice. Because of the temporal nature of this study, we were able to assess the causes of insulin resistance in the early stages of HFD-induced obesity, as well as later on in this process after obesity was well established. We found that glucose intolerance and systemic insulin resistance developed by 3 days of HFD. The systemic insulin resistance steadily worsened with increasing adipose tissue inflammation, and the temporal sequence and magnitude of initiation and progression of decreased insulin sensitivity was comparable in muscle, adipose tissue, and liver. Concurrently, a variety of markers of inflammation can be readily detected in adipose tissue, by as early as 3 days, and progressively increased throughout the 10-week HFD-feeding period. However, in liver and skeletal muscle, increased inflammation became apparent only after several weeks into the HFD period, after obesity was well established (Fig. 4). Furthermore, depletion of macrophages or Kupffer cells by clodronate-liposomes or gadolinium administration or disruption of macrophage inflammatory pathways by JNK1 deletion did not attenuate the early stage of insulin resistance (Fig. 7 and Supplementary Fig. 5). In contrast, these maneuvers substantially ameliorated insulin resistance at 14 weeks of HFD, at a time when severe obesity was established (Supplementary Fig. 6). Thus, our data suggest that macrophage-mediated tissue inflammation is a key component of chronic obesity–associated insulin resistance but is not critical for the decrease in insulin sensitivity, which develops at the early stage of HFD feeding.
Our data indicate that the inflammation elicited by short-term HFD was not sufficient to induce insulin resistance. Although elevation of inflammatory gene expression in adipose tissue and macrophage infiltration were significant at 3 days of HFD, the fold of increase by 3 or 7 days of HFD was much lower than that observed by 16 weeks of HFD (Fig. 4). Moreover, inflammation in muscle and liver was not observed during short-term HFD, in contrast with long-term 16-week HFD, suggesting that inflammation initiated in adipose tissue by short-term HFD was not able to propagate to other tissues as to induce insulin resistance.
Within the first several days of HFD, changes in circulating adipocytokine concentrations were observed (decreased adiponectin, increased TNF-α, and IL-6), which could contribute to decreased systemic insulin sensitivity, suggesting that acute induction of adipose tissue dysfunction might play important roles in short-term HFD-induced systemic insulin resistance. However, it is interesting to note that although insulin resistance progressively worsened from 3 days to 10 weeks, no further changes in adipocytokine levels were detected, indicating that some other mechanism must be responsible for the steady progression of the degree of insulin resistance. The chronic tissue inflammatory state is an excellent candidate for this mechanism, since accumulation of proinflammatory macrophages in adipose tissue gradually increased throughout the 10-week study period, and the increase in ATMs correlated very well with the magnitude of the insulin resistance (Fig. 4). Furthermore, increased inflammation in muscle and liver was only detected in the later stages of HFD, as systemic insulin resistance worsened. Thus, chronic tissue inflammation is at least one major cause of systemic insulin resistance associated with the obese state.
A possible mechanism for the early phase of insulin resistance seems to also relate to the lipid overload observed at the onset of HFD. It has been shown that intravenous lipid infusions rapidly cause systemic insulin resistance in humans and mice (9,11,21–25) and that this can be blunted by genetic ablation of PKCθ (10). This is associated with increased cellular levels of DAGs, ceramides, and other lipid-derived molecules, and this process of lipid-induced insulin resistance is termed lipotoxicity. Indeed, we observed that ceramide, DAG, and NEFA levels were increased in muscle and liver by 3 days of HFD and were not affected by clodronate treatment (Fig. 8). Thus, it seems possible that the large excess lipid intake at the onset of HFD would trigger decreased insulin sensitivity through an acute lipotoxic mechanism, whereas chronic tissue inflammation emerges as a key cause of insulin resistance during the established stage of obesity. It is of interest that the timing of the onset and the progressive worsening of the insulin resistance is comparable across the three major insulin target tissues, muscle, liver, and fat, despite the fact that the underlying mechanisms evolve during transition from the early to the later stages of HFD feeding and development of obesity.
Glucose intolerance, as well as increased HGP, was observed by 3 days of HFD and did not worsen throughout the next 10 weeks; i.e., these changes were nonprogressive. In contrast, although insulin resistance was readily detected by 3 days of HFD, it was progressively more severe by 1 week and then even more so by 10 weeks. This raises the question as to why glucose intolerance does not worsen with the progression of insulin resistance. A likely reason relates to the circulating insulin levels. Insulin levels are substantially higher at the later stages of HFD, compared with the earlier time points (Fig. 2B). This indicates that progressive hyperinsulinemia, most likely as a result of increasing β-cell hyperplasia (data not shown), increases over the later stages of HFD, compensating for the worsening insulin resistance state. However, this compensation does not reregulate glucose tolerance to normal but maintains glucose tolerance at the same level as observed during the initial 3-day HFD time point.
Recently, it has been found that adipose inflammation and increased ATM infiltration in obesity is accompanied by changes in subpopulations of T cells such as Tregs and CD8+ T cells residing in adipose tissue (26,27). We observed that the total number of Tregs in the epididymal adipose tissue was not decreased at any point during the 10-week HFD period, whereas the ratio of Tregs to the other cell types in SVCs, especially to M1-like macrophages, decreased significantly (Fig. 3A). These results are consistent with the view that passive changes in Treg ratios in adipose tissue, but not active suppression of Treg infiltration or proliferation, can be correlated with adipose tissue remodeling and ATM accumulation, conferring adipose tissue inflammation. Although this relative change in Treg proportions might contribute to migration or activation of ATMs, the macrophages would likely still be the effector cells promoting decreased insulin sensitivity in obesity. Moreover, lymphocyte-deficient Rag1 KO mice were not protected from short-term HFD-induced insulin resistance and glucose intolerance, or ATM accumulation (Fig. 6). Therefore it is likely that lymphocytes do not significantly contribute to short-term HFD-induced insulin resistance and adipose tissue inflammation.
In summary, we have assessed the temporal events underlying the development of insulin resistance during high-fat feeding. We found that decreased systemic insulin sensitivity appears early in the course of HFD and progressively increases at similar rates in muscle, liver, and adipose tissue. Interestingly, different mechanisms appear to evolve over the 10-week HFD period; i.e., lipid overload and lipotoxicity are more important early on, whereas chronic inflammation emerges as a more dominant mechanism once obesity is established toward the end of the HFD period.
This work was supported by grants from the Korea Science and Engineering Foundation funded by the Korean government (Ministry of Education, Science and Technology; SC-3230, 2009-0091913, 20110018312, and R312009000100320); by the National Institutes of Health (NIH) grants DK-033651, DK-074868, T32-DK-007494, and DK-063491; and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development/NIH through cooperative agreement of U54-HD-012303-25 as part of the specialized Cooperative Centers Program in Reproduction and Infertility Research. J.Y.H., I.J.H., and J.I.K. were supported by a BK21 Research Fellowship from the Ministry of Education and Human Resources Development.
No potential conflicts of interest relevant to this article were reported.
Y.S.L. wrote the manuscript and researched data. P.L., J.Y.H., I.J.H., M.L., J.I.K., M.H., S.T., A.C., W.J.L., and G.K.B. researched data. R.S. researched data and reviewed and edited the manuscript. J.O. and J.B.K. contributed to discussion and reviewed and edited the manuscript.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0194/-/DC1.
- Received February 15, 2011.
- Accepted June 13, 2011.
- © 2011 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.